Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, ...

Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

A roundup of the most newsworthy healthcare announcements from PR Newswire this week, including the FDA's nicotine reduction ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Barclays analyst Peter Lawson assigned a Buy rating to Relay Therapeutics (RLAY – Research Report) today and set a price target of $17.00. The ...

This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...